MedTrace Logo

Investigating a Vaccine Against COVID-19

NCT04400838 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 10811

Last updated 2025-09-03

No results posted yet for this study

Summary

A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in healthy UK volunteers.

Conditions

  • Coronavirus

Interventions

BIOLOGICAL

ChAdOx1 nCoV-19 (Abs 260)

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260

BIOLOGICAL

MenACWY vaccine

Standard single dose of MenACWY vaccine

BIOLOGICAL

ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260 and 2.2x10\^10vp ChAdOx1 nCoV-19 boost measured by qPCR 4-6 weeks later

BIOLOGICAL

Two dose MenACWY vaccine

Two standard doses of MenACWY vaccine 4-6 weeks apart

BIOLOGICAL

ChAdOx1 nCoV-19 (qPCR)

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by qPCR

BIOLOGICAL

ChAdOx1 nCoV-19 0.5mL prime plus boost

Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)

BIOLOGICAL

Two dose MenACWY vaccine min. 4 weeks apart

Two standard doses of MenACWY vaccine minimum 4 weeks apart

BIOLOGICAL

Two dose ChAdOx1 nCoV-19/Covishield 0.5mL

Two dose ChAdOx1 nCoV-19 0.5mL (Covishield 0.9 x 10\^11 vp/mL), 4-6 weeks apart

BIOLOGICAL

Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL

Two dose ChAdOx1 nCoV-19 (Covishield 0.9 x 10\^11 vp/mL), 0.25mL prime and 0.5mL boost 4-6 weeks apart

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Andrew Pollard, Prof · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-28
Primary Completion
2025-02-05
Completion
2025-02-05

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04400838 on ClinicalTrials.gov